Welcome to our dedicated page for Mesa Laboratories news (Ticker: MLAB), a resource for investors and traders seeking the latest updates and insights on Mesa Laboratories stock.
Mesa Laboratories, Inc. (MLAB) provides critical quality control solutions for pharmaceutical, healthcare, and life sciences industries through its sterilization monitoring, calibration systems, and biopharmaceutical development tools. This page aggregates official press releases and verified news updates essential for tracking the company’s operational and regulatory developments.
Investors and industry professionals will find timely updates on earnings reports, product launches, regulatory milestones, and strategic partnerships. All content is sourced directly from the company or reputable financial publications to ensure accuracy in this fast-moving sector.
Key focus areas include innovations in sterilization validation technologies, advancements in clinical genomics tools, and updates to compliance standards affecting medical device manufacturing. The curated collection serves as a reliable resource for understanding how MLAB addresses evolving challenges in quality assurance for regulated environments.
Bookmark this page for streamlined access to Mesa Laboratories’ latest developments, or check back regularly to stay informed about this essential player in life sciences infrastructure.
Mesa Laboratories (NASDAQ: MLAB) has announced a quarterly dividend of $0.16 per share of common stock. The dividend is scheduled for payment on September 16, 2024, to shareholders who are on record as of August 30, 2024.
Mesa Laboratories specializes in designing and manufacturing life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device industries. The company's products and services aim to ensure product integrity, enhance patient and worker safety, and improve global quality of life.
Mesa Laboratories (NASDAQ: MLAB) reported its fourth quarter and full fiscal year 2024 results. In 4Q24, revenues rose by 6% compared to 4Q23, reaching $58,904, driven by the acquisition of GKE China. However, core organic revenues fell by 3.5%. The company also registered an operating loss of $271,284, due to a significant non-cash impairment charge. Non-GAAP adjusted operating income surged by 26.3%.
For FY24, revenues decreased by 1.3% to $216,187, with core organic revenues dropping 5.4%. The year saw an operating loss of $272,075. Non-GAAP adjusted operating income grew by 0.7%. Mesa Labs' financial performance was impacted by economic slowdowns and headwinds in the biopharmaceutical and clinical genomics sectors, despite gains in other areas and effective cost control measures.
Mesa Laboratories (NASDAQ: MLAB) announced a delay in issuing its unaudited fourth quarter and full fiscal year 2024 financial results, initially scheduled for today. The delay is due to the finalization of year-end audit calculations and technical accounting for previously announced impairments in its Clinical Genomics and Biopharmaceutical Development divisions, as well as purchase accounting for GKE's acquisition. The Form 10-K filing deadline with the SEC is June 14, 2024. Mesa Laboratories is a global leader in life sciences tools and quality control solutions for regulated pharmaceutical, healthcare, and medical device industries.
Mesa Laboratories (NASDAQ:MLAB) has revised the earnings announcement date for its unaudited fourth quarter and full fiscal year 2024 results to May 31, 2024. The press release, disclosing financial outcomes for the period ending March 31, 2024, will be issued at approximately 8:00 A.M. Eastern time on that day.
Mesa's Form 10-K, detailing these results, will also be filed on May 31. The delay is attributed to finalizing calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill in the Clinical Genomics and Biopharmaceutical Development divisions. The deadline for this filing with the SEC is June 14, 2024.
Mesa Laboratories specializes in life sciences tools and critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, ensuring product integrity and improving quality of life globally.
FAQ
What is the current stock price of Mesa Laboratories (MLAB)?
What is the market cap of Mesa Laboratories (MLAB)?
